About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

    <<
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    >>

%SEDAR: 00013053E

SOURCE: MEDMIRA INC.

Andrea Young, MedMira, (902) 450-1588, ayoung@medmira.com

"Similar to the US Food and Drug Administration's medical device regulations, this new classification allows MedMira to overcome a major hurdle in accessing the lucrative China market and we make another step forward in our long term business development plan for the Asia Pacific region," said Hermes Chan, CEO, MedMira Inc. "Local manufacturing is in place, our strategic sales and distribution partner, Triplex, is now up and running, and new markets are open to us with this new classification. With all of these favorable market conditions aligned and a shortened sales cycle we are now positioned to recognize an increase in revenue from rapid HIV tests sales in China in the coming quarters."

Classified as a drug product by the country's regulators since its initial market entry in 2004, MedMira had experienced a number of complex market barriers in selling its rapid HIV test in large volumes throughout China. The new medical device classification means greater flexibility in regulatory guidelines, making it logistically easier to sell the rapid HIV test in all regions and all healthcare sectors in China.

"We are exploring every sales opportunity for MedMira's rapid HIV test and look forward to increasing sales of this key product in the coming months," said Yiu Ming Fung, President and Chairman of Triplex International Biosciences Co., Ltd. "This newly granted approval under the medical device classification is a significant step forward in proactively promoting and selling the product in all segments of our market and is also setting the stage for the pending regulatory approvals of the five additional MedMira rapid tests we are currently adding to our product portfolio."

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

    <<
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    >>

%SEDAR: 00013053E

SOURCE: MEDMIRA INC.

Andrea Young, (902) 450-1588, ayoung@medmira.com

MedMira has also developed, in collaboration with Triplex, the single and multiple rapid tests for drugs of abuse such as amphetamines, methamphetamines, morphine, barbital, benzodiazepine, cocaine, THC, and ketamine. The multiple test can detect up to five of these drugs in just a few drops of urine. These new products will answer the demand for faster, more streamlined drug testing to combat the growing problem of drug abuse among the youth population in Hong Kong and Mainland China. According sources in Hong Kong, drug abuse among those under 21 has increased by 57% in the past four years. Local authorities are stepping up efforts to reverse the trend and battle the growing use of ketamine in particular, including random school-based drug tests.

"Expanding our product line with Triplex at this time is a very good opportunity for us to meet the increasing demand for advanced rapid diagnostics for drugs of abuse and other initiatives being implemented as China's new healthcare system takes shape," said Hermes Chan, CEO, MedMira Inc. "Our world class diagnostics technology and applications together with Triplex's local market knowledge, a well-established customer base, and access to healthcare experts, will move MedMira's market presence in Mainland China and Hong Kong forward."

Earlier this year the two companies established a strategic partnership to distribute MedMira rapid tests through Triplex and explore other market opportunities in China. Triplex is a major player in the China diagnostics market, with recorded sales revenue of nearly USD $30 million last year.

"We are pleased to bring additional MedMira rapid tests to our customers in Mainland China and Hong Kong. The multiple test for drugs of abuse will be the first of its kind in this market and answer a growing demand for reliable and fast drug tests," said Yiu Ming Fung, President and Chairman of Triplex. "We look forward to further expanding our partnership with MedMira in the near future with a focus on the co-development of new rapid tests for cancer and heart disease markers."

About Triplex International Biosciences Co., Ltd.

Triplex is one of the leading molecular pathology diagnostic companies in China and its line of diagnostic solutions is one of the tope brands in the industry. Over the past five years, Triplex has grown from seven people to a team of 170 supporting the Company's annual sales growth rate of 400 percent. Triplex sells more than 45 products to over 2000 hospitals and medical institutions across 29 provinces and cities in China. The Company has also developed more than 30 diagnostic products through its Engineering Laboratory for Molecular Diagnostic Technology in Fuzhou, three R&D centers, and five joint R&D bases with Peking University Medical School, the Fourth Military Medical University in Xi-an, Sichuan University, Fujian Medical University, as well as CAS Shanghai Life Sciences Research Institute. To learn more about Triplex visit www.tibchina.com.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

    <<
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    >>

%SEDAR: 00013053E

SOURCE: MEDMIRA INC.

SOURCE: Triplex International Biosciences Co., Ltd.

Andrea Young, MedMira, (902) 450-1588, ayoung@medmira.com